# Collegium Pharmaceutical

Type: Company (COLL)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/collegium-pharmaceutical
Canonical HTML page: https://getfinancebrief.com/entity/collegium-pharmaceutical

## Recent coverage (2 stories)

### COLL Beats Q2 EPS by $0.20, Stock Gains 1.24% to $29.47
2026-08-09 18:28:55 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Collegium Pharmaceutical delivered an 11.6% EPS beat and modest revenue beat, lifting shares to $29.47. High ROE and institutional accumulation offset by high leverage and mixed analyst ratings create a nuanced investment case.
Full story: https://getfinancebrief.com/story/collegium-pharma-q2-2026-earnings-finance

### Pharma Earnings: Wave Life Sciences and Collegium Report 2025 Results
2026-02-26 14:29:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences and Collegium Pharmaceutical released their full-year 2025 financial results, highlighting a pivotal year for RNA therapeutics and specialty pain management. While Wave focuses on clinical milestones for its RNA editing platform, Collegium is driving growth through its commercial ADHD and pain portfolios.
Full story: https://getfinancebrief.com/story/wave-life-sciences-collegium-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.